The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
Open accessAbstract
Metabolic reprogramming by oncogenic signals promotes cancer initiation and progression. The oncogene KRAS and tumour suppressor STK11, which encodes the kinase LKB1, regulate metabolism and are frequently mutated in non-small-cell lung cancer (NSCLC). Concurrent occurrence of oncogenic KRAS and loss of LKB1 (KL) in cells specifies aggressive oncological behaviour. Here we show that human KL cells and tumours share metabolomic signatures of perturbed nitrogen handling. KL cells express the urea cycle enzyme carbamoyl phosphate synthetase-1 (CPS1), which produces carbamoyl phosphate in the mitochondria from ammonia and bicarbonate, initiating nitrogen disposal. Transcription of CPS1 is suppressed by LKB1 through AMPK, and CPS1 expression correlates inversely with LKB1 in human NSCLC. Silencing CPS1 in KL cells induces cell death and reduces tumour growth. Notably, cell death results from pyrimidine depletion rather than ammonia toxicity, as CPS1 enables an unconventional pathway of nitrogen flow from ammonia into pyrimidines. CPS1 loss reduces the pyrimidine to purine ratio, compromises S-phase progression and induces DNA-polymerase stalling and DNA damage. Exogenous pyrimidines reverse DNA damage and rescue growth. The data indicate that the KL oncological genotype imposes a metabolic vulnerability related to a dependence on a cross-compartmental pathway of pyrimidine metabolism in an aggressive subset of NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS/LKB1-null lung cancer cells are more reliant on the urea cycle enzyme carbamoyl phosphate synthetase-1 (CPS1) for pyrimidine biosynthesis, although this dependency is independent of mTOR signaling (Kim et al., 2017).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Kim et al., 2017
In the citing paper
“Interestingly, the first step in de novo pyrimidine biosynthesis mediated by CPSs occurs mainly in mitochondria via CPS1 in K-Ras/LKB1-mutant lung cancer cells32 (Fig. 2).”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [32]
In the citing paper
“Although cytosolic CPS2 can produce a cytosolic pool of carbamoyl phosphate, CPS1 is a major rate-limiting enzyme in pyrimidine biosynthesis using nitrogen released via mitochondrial glutaminolysis32.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [32]
In the citing paper
“Furthermore, KL NSCLC cells exhibit increased dependence on dTTP synthesis and rely on an unorthodox pathway of pyrimidine biosynthesis that utilizes mitochondrially generated carbamoyl phosphate88, 89.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Jackson, D., & Pombo, A. (1998) · Journal of Cell Biology · doi:10.1083/jcb.140.6.1285 · Cited by 881
Petermann, E., Orta, M. L., Issaeva, N., Schultz, N., & Helleday, T. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.021 · Cited by 815
INTERACTIONS BETWEEN DEOXYRIBONUCLEOTIDE AND DNA SYNTHESIS
Reichard, P. A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002025 · Cited by 773
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–333 of 333
TP53-dependent antitumor effects of DHODH Inhibition in nasopharyngeal carcinoma
Dong, X., Zhang, Y., Zhang, Z., Liu, T., & Gu, D. (2025) · Discover Oncology · doi:10.1007/s12672-025-03857-6
Zheng, T., Huang, J., Xiang, X., Li, S., Yu, J., Qu, K., Xu, Z., Han, P., Dong, Z., Liu, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16800371
Liu, Y., Wu, M., Xu, S., Niu, X., Liu, W., Miao, C., Lin, A., Xu, Y., & Yu, L. (2024) · Figshare · doi:10.6084/m9.figshare.26579132
Liu, Y., Wu, M., Xu, S., Niu, X., Liu, W., Miao, C., Lin, A., Xu, Y., & Yu, L. (2024) · Figshare · doi:10.6084/m9.figshare.26579135
Oruganty, K., Campit, S., Mamde, S., Lyssiotis, C. A., & Chandrasekaran, S. (2020) · Figshare · doi:10.6084/m9.figshare.12270170
Li, C., Tan, H., Mao, Y., Liu, Y., Hu, J., Pang, X., Hou, X., & Minglin, O. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00695-y
Yang, Y., Ge, A., Xu, Y., Li, J., Shi, W., Wang, J., & Zhao, Z. (2026) · Future Science OA · doi:10.1080/20565623.2025.2610162
Zhang, Q., Wu, D., Guo, F., Yang, S., Bao, L., Zhang, R., & Wang, P. (2026) · Digestion · doi:10.1159/000549887
RetractedCPS1: a multipurpose mitochondrial enzyme, bile protein, acute liver injury biomarker, and cytokine
Chen, L., Li, P., Park, M.-J., Chen, Z., & Omary, M. B. (2026) · Gut · doi:10.1136/gutjnl-2024-333082
NFATC2-mediated CST1 upregulation drives cholangiocarcinoma growth and metastasis
Zhao, W., Zhao, J., Li, K., Shi, J., Cong, L., & Yu, G. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03036-8
Self-citationMetabolic Mayhem in the Tumor Microenvironment: Can Mesenchymal Stromal Cells Restore Order?
Abou‐Shanab, A. M., Khairy, A., Hany, F., & El‐Badri, N. (2026) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-032-12705-1_8
A proteomic approach for understanding the metabolic adaptations in non-small cell lung cancer
Martín-Bernabé, A. (2018) · theses.fr (ABES) · doi:10.70675/426e7b40z057az4326z8cfez7da3a5c12c7e
Bondarenko, M. (2021) · theses.fr (ABES) · doi:10.70675/b6c8631azd6aaz42e9z9cf3z65208b9697a3
Rôles du NAD dans la plasticité cellulaire cancéreuse
Gouasmi, R. (2025) · theses.fr (ABES) · doi:10.70675/4c8cef97z8e4fz4245z8588z8d740f2b17fe
Xu, L., Zheng, D., Zhang, J., Hu, H., Dong, L., & Chen, E. (2026) · Discover Oncology · doi:10.1007/s12672-026-05038-5
Nucleotide Metabolism and DNA Repair: Implications in Cancer Treatments
Priyadarshi, N., Abbas, F. E., Thakur, D., Thakur, S., & Dilawari, R. (2026) · DNA · doi:10.3390/dna6020025
Liao, S., Huang, Z., Liu, X., Wang, K., Zheng, Z., Li, Y., Liu, S., Dai, Z., Yang, M., Jiang, L., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08357-x
Ye, Z., Wu, H., Li, Z., Ye, R., 饶应良, Liu, B., & Gao, B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1826809
The Role of Urea Cycle Functional Studies in Preclinical Research
Breuillard, N., Zürcher, N., Faccin, E., Stocker, K. L., Poms, M., & Häberle, J. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70225
Yang, D., Wu, X., Luo, X., Teng, Y., Duan, X., Kang, T., & Wu, W. (2026) · Biomedical Chromatography · doi:10.1002/bmc.70560
Targeting LKB1-inactivated lung cancers with a stapled peptide inhibitor of the CRTC-CREB pathway
Zhou, X., Bird, G. H., Yu, M., Li, J., Solone, X. K., Chung, M. C., Guan, J., Walensky, L. D., & Wu, L. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201331
STK11/LKB1 Loss in Cancer: From Developmental Constraint to Stress-Adapted Malignancy
Kang, Y., Gao, Y., Zhang, X., Liu, H.-O., Xu, C., & Huo, Y. (2026) · Cancers · doi:10.3390/cancers18172845
Li, G., He, Z., Liu, M., Zhao, J., Zhu, H., Zhou, C., Wang, Z., He, X., Tang, J., & Jiang, P. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01586-w
Najar, M. A., Choudhary, N., Dwivedi, N., & Modi, P. K. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00428
Tumor organoids for testing metabolic flexibility in precision oncology
Hao, D., Ren, Y., & Zhang, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1902688
A blood-based metabolic signature for earlier detection of lung cancer
Irajizad, E., Rudsari, H. K., Gendarme, S., Vykoukal, J., Wu, R., Dennison, J. B., Karimi, N., Darbaniyan, F., Javad, M. S., Do, K.-A., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103059
Gu, L., Liu, M., Li, Y., Zhou, H., Wang, Y., & Xu, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1952846
Targeting metabolic cell death in cancer to reverse drug resistance
Liu, T., Dang, Y., Zhang, W., Liu, Y., Ji, Y., Lu, P., Zou, H., Yang, W., & JIANG, J. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189737
Lung cancer metabolism: a dynamic and adaptive network
Najjar, S. G., & Frezza, C. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06417-5
Choi, Y.-J., Kim, J., Mai, X. L., de Guzman, A. C. V., An, Y. J., Kim, H. S., Cho, B., & Park, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1926332
Self-citationBindingDB Entry 50010782: Discovery of 2,6-Dimethylpiperazines as Allosteric Inhibitors of CPS1.
BindingDB (2021) · UC San Diego · doi:10.7270/q2x92fvf
Research Progress on Argininosuccinate Synthetase 1 in Tumor Metabolism and Precision Therapy
刘, 佳. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.16103561
Adaptive Rewiring of Nucleotide Metabolism in Therapeutic Resistance
Dayanc, B., Xu, G., Zhou, X., Chen, J., Mueller, N., Kaur, H., Pham, B., Yoda, S., & Schneider, J. L. (2026) · Cancers · doi:10.3390/cancers18213498
Metadata
- Authors
- Kim, J., Hu, Z., Cai, L., Li, K., Choi, E., Faubert, B., Bezwada, D., Rodriguez-Canales, J., Villalobos, P., Lin, Y.-F., Ni, M., Huffman, K. E., Girard, L., Byers, L. A., Unsal-Kacmaz, K., Peña, C. G., Heymach, J. V., Wauters, E., Vansteenkiste, J., Castrillon, D. H., Chen, B. P. C., Wistuba, I., Lambrechts, D., Xu, J., Minna, J. D., & DeBerardinis, R. J.
- Affiliations
- Children's Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- KU Leuven (BE)
- VIB-KU Leuven Center for Cancer Biology (BE)
- Corresponding author
- DeBerardinis, Ralph J.
- ORCID
- Venue
- Nature
- Published
- 2017-05-24
- Volume
- 546
- Issue
- 7656
- Pages
- 168-172
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5472349
- OpenAlex
- W2619620886
- Cited by
- 325
- References
- 30
- Citations by year
- 2026: 39 · 2025: 40 · 2024: 26 · 2023: 42 · 2022: 38 · 2021: 45 · 2020: 38 · 2019: 26 · 2018: 27 · 2017: 4
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-05-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- National Cancer Institute (P50CA070907, U01CA176284, R01CA196912, R01CA157996)
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK093543, R01DK111430)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- CPS1, LKB1, KRAS mutation, non-small cell lung cancer, lung adenocarcinoma, pyrimidine metabolism, urea cycle, nitrogen metabolism, DNA synthesis, DNA damage, AMPK, tumor metabolic reprogramming, S phase progression, tumor suppressor loss
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Ammonia, Animals, Bicarbonates, Carbamyl Phosphate, Carbamoyl-Phosphate Synthase (Ammonia), Carcinoma, Non-Small-Cell Lung, DNA, DNA Damage, DNA-Directed DNA Polymerase, DNA Replication, Female, Humans, Lung Neoplasms, Male, Mitochondria, Nitrogen, Purines, Pyrimidines, Transcription, Genetic, S Phase, Proto-Oncogene Proteins p21(ras), Cell Death, Protein Serine-Threonine Kinases, Gene Silencing, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, AMP-Activated Protein Kinases, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
